Gilmartin Group LLC

Congratulations to our client, Kanglin Biotechnology, on announcing the successful completion of a $20 million Series A financing to advance the development the next generation of gene therapies for the treatment of beta thalassemia, AIDS, hemophilia and Parkinson's disease. Official press release: https://lnkd.in/g4SzUKV5

GILMARTIN BLOG: Effective #AI governance is not just a regulatory necessity; it is also a strategic move that can significantly enhance a company’s credibility and appeal to investors, positioning it for long-term success and sustainable growth. In the latest Gilmartin blog post, we discuss key best practices for AI governance that can help safeguard both operational integrity and investor trust. Read the full blog post: https://lnkd.in/gR9W7esc

It’s been an exciting week for our clients as they took center stage at multiple conferences, sharing insights and innovation. We're proud to support our clients and their ongoing success.

Gilmartin is hiring! We're seeking passionate and motivated Investor Relations Analysts to join our growing teams in New York City and San Diego. We look forward to hearing from you!

Gilmartin is excited to join the first annual CG Life Sweat Equity 5K Run at the 2025 JPM Healthcare Conference in San Francisco! We’re looking forward to connecting with everyone at the run and throughout the conference alongside our friends at CG Life, STAT and MC Services. See you there. #JPM2025

Congratulations to Cardiff Oncology for the publication of their Phase 2 clinical trial results in the American Society of Clinical Oncology (ASCO) Journal of Clinical Oncology. Key highlights from the study include: -?????A 77% objective response rate in bev-na?ve patients, compared to just 10% in those previously exposed. -?????A median progression-free survival of 14.9 months for bev-na?ve patients, demonstrating significant clinical benefit -?????New discovery that onvansertib exhibits antitumor activity in combination with bev through the inhibition of angiogenesis. Full press release here: https://lnkd.in/eq7Wr9tJ

Congratulations to Eledon Pharmaceuticals, Inc. on announcing positive initial data from the first three subjects with type 1 diabetes treated with tegoprubart as part of an immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine. The data demonstrated potentially the first human cases of insulin independence achieved using an anti-CD40L monoclonal antibody therapy without the use of tacrolimus, the current standard of care for prevention of transplant rejection. In addition, today Eledon also announced the pricing of an $85M underwritten offering. Learn more about the clinical trial and patient impact covered by ABC News: https://lnkd.in/gwmcHfMm

Recent guidance from the U.S. Securities and Exchange Commission (SEC) and other regulatory bodies makes clear that transparency, specificity, and board-level oversight are critical to AI-related disclosures.?In Gilmartin's latest blog post, we're recapping key takeaways from the recent NIRI: The Association for Investor Relations 2024 AI Summit and discussing how to navigate transparency and accountability in corporate disclosures in today's #AI landscape. Read the full blog post: https://lnkd.in/gnR4V9F3

Gilmartin was happy to once again sponsor the Wilson Sonsini Goodrich & Rosati Phoenix Conference in Half Moon Bay this week. Thank you to the team at Wilson Sonsini for having us.

A big thank you to JLABS for hosting Gilmartin at the JLABS Global CEO Summit this week at the NYSE. Gilmartin Biotech Managing Director Monique Kosse participated in a panel on Scaling Up & Getting Ready for an IPO. We enjoyed connecting with leaders in the space and the insightful discussion.